Search

Your search keyword '"ALTIPARMAK, Mehmet Rıza"' showing total 13 results
Start Over Author "ALTIPARMAK, Mehmet Rıza"
13 results on '"ALTIPARMAK, Mehmet Rıza"'

1. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Author

Fragale, Guillermo, Karl, Alejandra, Losisolo, Patricia, Trimarchi, Hernán, Hoyos, Ivan Gonzalez, Lampo, Mauro Guillermo, Monkowski, Matias, De La Fuente, Jorge, Alvarez, Magdalena, Stoppa, Daniela, Chiurchiu, Carlos, Novoa, Pablo Antonio, Orias, Marcelo, Barron, Maria Belen, Giotto, Ana, Arriola, Mariano, Cassini, Evelin, Maldonado, Rafael, Dionisi, Maria Paula, Ryan, Jessica, Toussaint, Nigel, Luxton, Grant, Peh, Chen Au, Levidiotis, Vicki, Francis, Ross, Phoon, Richard, Fedosiuk, Elena, Toropilov, Dmitry, Yakubtsevich, Ruslan, Mikhailova, Elena, Bovy, Christophe, Demoulin, Nathalie, Hougardy, Jean-Michel, Maes, Bart, Speeckaert, Marijn, Laurin, Louis-Philippe, Barbour, Sean, Masse, Melanie, Hladunewich, Michelle, Reich, Heather, Cournoyer, Serge, Tennankore, Karthik, Lv, Jicheng, Liu, Zhangsuo, Wang, Caili, Li, Shaomei, Luo, Qun, Ni, Zhaohui, Yan, Tiekun, Fu, Ping, Cheng, Hong, Liu, Bicheng, Lu, Wanhong, Wang, Jianqin, Chen, Qinkai, Wang, DeGuang, Xiong, Zuying, Chen, Menghua, Xu, Yan, Wei, Jiali, Pai, Pearl, Chen, Lianhua, Rehorova, Jitka, Maixnerova, Dita, Safranek, Roman, Rychlik, Ivan, Hruby, Miroslav, Makela, Satu, Vaaraniemi, Kati, Ortiz, Fernanda, Alamartine, Eric, Daroux, Maite, Cartery, Claire, Vrtovsnik, Francois, Serre, Jean-Emmanuel, Stamellou, Eleni, Vielhauer, Volker, Hugo, Christian, Budde, Klemens, Otte, Britta, Nitschke, Martin, Ntounousi, Evangelia, Boletis, Ioannis, Papagianni, Aikaterini, Goumenos, Dimitrios, Stylianou, Konstantinos, Zermpala, Synodi, Esposito, Ciro, Cozzolino, Mario Gennaro, Viganò, Sara Maria, Gesualdo, Loreto, Nowicki, Michal, Stompor, Tomasz, Kurnatowska, Ilona, Kim, Sung Gyun, Kim, Yong-Lim, Na, Ki-Ryang, Kim, Dong Ki, Kim, Su-Hyun, Porras, Luis Quintana, Garcia, Eva Rodriguez, Pamplona, Irene Agraz, Segarra, Alfons, Goicoechea, Marian, Fellstrom, Bengt, Lundberg, Sigrid, Hemmingsson, Peter, Guron, Gregor, Sandell, Anna, Chen, Cheng-Hsu, Tokgoz, Bulent, Duman, Soner, Altiparmak, Mehmet Riza, Ergul, Metin, Maxwell, Peter, Mark, Patrick, McCafferty, Kieran, Khwaja, Arif, Cheung, Chee Kay, Hall, Matthew, Power, Albert, Kanigicherla, Durga, Baker, Richard, Moriarty, Jim, Mohamed, Amr, Aiello, Joseph, Canetta, Pietro, Ayoub, Isabelle, Robinson, Derrick, Thakar, Surabhi, Mottl, Amy, Sachmechi, Isaac, Fischbach, Bernard, Singh, Harmeet, Mulhern, Jeffrey, Kamal, Fahmeedah, Linfert, Douglas, Rizk, Dana, Wadhwani, Shikha, Sarav, Menaka, Campbell, Kirk, Coppock, Gaia, Luciano, Randy, Sedor, John, Avasare, Rupali, Lau, Wai Lang, Barratt, Jonathan, Lafayette, Richard, Kristensen, Jens, Stone, Andrew, Cattran, Daniel, Floege, Jürgen, Tesar, Vladimir, Zhang, Hong, Eren, Necmi, Paliege, Alexander, and Rovin, Brad H.

Published
2023
Full Text
View/download PDF

2. The Longitudinal Evolution of Post–COVID-19 Outcomes Among Hemodialysis Patients in Turkey

Author

Ozturk, Savas, Turgutalp, Kenan, Arici, Mustafa, Gorgulu, Numan, Tonbul, Halil Zeki, Eren, Necmi, Gencer, Vedat, Ayli, Mehmet Deniz, Pembegul, Irem, Dolarslan, Murside Esra, Ural, Zeynep, Colak, Hulya, Ozler, Tuba Elif, Can, Ozgur, Demir, Mehmet Emin, Altunoren, Orcun, Huddam, Bulent, Onec, Kursad, Demirelli, Bulent, Aydin, Zeki, Altun, Eda, Alagoz, Selma, Ayar, Yavuz, Eser, Zeynep Ebru, Berktas, Bayram, Yilmaz, Zulfukar, Ates, Eser Uslu, Yuksel, Enver, Sahin, Gizem Kumru, Aktar, Merve, Cebeci, Egemen, Dursun, Belda, Kocak, Sibel Yucel, Yildiz, Abdulmecit, Kazan, Sinan, Gok, Mahmut, Sengul, Erkan, Tugcu, Murat, Ozturk, Ramazan, Kahvecioglu, Serdar, Kara, Ekrem, Kaya, Bulent, Sahin, Garip, Sakaci, Tamer, Sipahi, Savas, Kurultak, Ilhan, Durak, Beyza Algul, Altiparmak, Mehmet Riza, Ecder, Sabahat Alisir, Karadag, Serhat, Dincer, Mevlut Tamer, Ozer, Hakan, Bek, Sibel Gokcay, Ulu, Memnune Sena, Gungor, Ozkan, Bakir, Elif Ari, Odabas, Ali Riza, Seyahi, Nurhan, Yildiz, Alaattin, and Ates, Kenan

Published
2022
Full Text
View/download PDF

5. Antibody responses to the SARS‐CoV‐2 vaccines in hemodialysis patients: Is inactivated vaccine effective?

Author

Murt, Ahmet, Altiparmak, Mehmet Rıza, Yadigar, Serap, Yalin, Serkan Feyyaz, Ozbey, Dogukan, Yildiz, Zeynep, Kocazeybek, Bekir, Pekpak, Meltem, and Ataman, Muveddet Rezzan

Subjects
COVID-19 vaccines, VACCINE effectiveness, HEMODIALYSIS patients, ANTIBODY formation, HUMORAL immunity
Abstract

Introduction: Vaccines generally have reduced effectiveness in hemodialysis patients and a similar condition may also apply for the SARS‐CoV‐2 vaccines. The aim of this study was to analyze humoral responses of hemodialysis patients to SARS‐CoV‐2 vaccines. Methods: Eighty‐five maintenance hemodialysis patients who received either inactivated or mRNA SARS‐CoV‐2 vaccines were investigated. Antibody levels were measured by a commercial antibody kit, which detected antibodies toward receptor binding domain of the SARS‐CoV‐2 spike protein. Comparative analyzes were carried between vaccine groups and with a control group of 103 healthy volunteers. Results: Seropositivity rate and antibody levels were significantly lower in hemodialysis patients who received inactivated vaccine (p = 0.000). While mRNA vaccine had better immunogenicity, both vaccines protected from symptomatic infection when seropositivity was achieved. Discussion/Conclusion: When used in the same dose with the general population, inactivated SARS‐CoV‐2 vaccines generate reduced humoral response in hemodialysis patients. mRNA vaccines have better immunogenicity in this group. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

6. Impact of hospital-acquired acute kidney injury on Covid-19 outcomes in patients with and without chronic kidney disease: a multicenter retrospective cohort study

Author

ÖZTÜRK, Savaş, primary, TURGUTALP, Kenan, additional, ARICI, Mustafa, additional, ÇETİNKAYA, Hakkı, additional, ALTIPARMAK, Mehmet Rıza, additional, AYDIN, Zeki, additional, SOYPAÇACI, Zeki, additional, BORA, Feyza, additional, KARA, Ekrem, additional, CEBECİ, Egemen, additional, ÖZLER, Tuba Elif, additional, DÖLARSLAN, Mürşide Esra, additional, SİPAHİ, Savaş, additional, AYAR, Yavuz, additional, ŞAHİN, İdris, additional, BAKIRDÖĞEN, Serkan, additional, İSLAM, Mahmud, additional, GÖRGÜLÜ, Numan, additional, ÖĞÜTMEN, Melike Betül, additional, ŞENGÜL, Erkan, additional, GÜNGÖR, Özkan, additional, SEYAHİ, Nurhan, additional, TOKGÖZ, Bülent, additional, ODABAŞ, Ali Rıza, additional, TONBUL, Halil Zeki, additional, SEZER, Siren, additional, YILDIZ, Alaattin, additional, and ATEŞ, Kenan, additional

Published
2021
Full Text
View/download PDF

7. Analysis of Patients Who Underwent Hemodialysis in the Emergency Department

Author

AKTEPE, Melek, AKDENİZ, Yonca Senem, İPEKCİ, Afşın, ÇAKMAK, Fatih, ALTIPARMAK, Mehmet Rıza, and İKİZCELİ, İbrahim

Subjects
acil servis,akut böbrek hasarı,diyaliz, acute kidney injury,dialysis,emergency department, Acil Tıp, Emergency Medicine
Abstract

Amaç: Acil hemodiyaliz akut böbrek yetmezliği oluşan hastalarda hayat kurtarıcı bir tedavidir. Çalışmamızda acil serviste ilk kez hemodiyaliz tedavisi gören hastaların demografik ve klinik özellikleri ile beraber mortalitelerini etkileyen faktörlerin incelenmesi amaçlandı. Gereç ve Yöntem: Retrospektif olarak yapılan bu çalışmaya hastanemiz acil servisine başvuran ve hemodiyaliz ünitesinde, 1.1.2017 ile 1.1.2018 tarihleri arasında ilk kez hemodiyalize alınan 95 hasta alındı. Hastalar demografik, klinik ve laboratuvar verileri, diyaliz endikasyonları, 30 günlük sağ kalımları, yaşayan hastaların renal durumları, ölen hastaların ölüm sebepleri açısından değerlendirildi.Bulgular: Hastaların %62.1’i erkek, %37.9’u kadın, yaş ortalaması 62.28 yıl saptandı. Hastaların en sık diyalize alınma sebepleri metabolik asidoz ve kreatinin yüksekliği (%75) idi. Hastaların %41.1’ inin 30 gün içerisinde öldüğü görüldü. En sık ölüm sebebinin %64.1 malignite gibi altta yatan hastalıklara bağlı komplikasyonlar olduğu görüldü. Hastaların %7.4 ü tam iyileşme, %28.4 ü diyalize ihtiyaç duymayan kronik böbrek hastalığı, %64.2’si diyaliz hastası olarak taburcu olmuştur.Sonuç: Acil servise başvuran ve akut böbrek hasarı saptanan pek çok hasta anüri, hipervolemi, hiperpotasemi ve üremik bulgular nedeniyle hemodiyalize alınmaktadır. Bu hastaların otuz günlük mortalite oranları yüksektir ve en sık mortalite sebebi malignite gibi altta yatan hastalıklara bağlı komplikasyonlardır., Objectives: Hemodialysis is a life-saving treatment in patients with acute kidney injury. We aimed to compare the etiologic, laboratory, and clinical status and mortality rates of patients who underwent hemodialysis for the first time, as well as to determine the factors impacting mortality.Material and Method: 95 patients who apply to the emergency room and underwent hemodialysis for the first time in our hemodialysis unit between 1.1.2017 and 1.1.2018 were enrolled in this retrospective study. The patients were evaluated in terms of demographic, clinical, and laboratory data, dialysis indications, the mortality rate for 30 days, kidney disease status, and causes of death.Results: %62.1 of patients were male and 37.9% were female and the mean age was 62.28 years. Metabolic acidosis and creatinine increase (75%) were the most cause of dialysis. 41.1% of patients died in 30 days. The most common cause of death was complications due to underlining concomitant illnesses like malignancy (64.1%). 7.4% of patients were recovered completely, 28.4% of patients had chronic renal disease without any renal replacement therapy, 64.2% of patients were dialysis patients at the discharge from the hospital.Conclusion: Most of the patients who access the emergency room, because of anuria, hypervolemia, hyperpotasemia, and uremic symptoms, is taken to hemodialysis. These patients have approximately 40% mortality rate in 30 days of survival, and the primary cause of mortality is complications due to underlining concomitant diseases.

Published
2020

10. Türkiye'de Renal Replasman Tedavilerinin Güncel Durumu: Türk Nefroloji Derneği Kayıt Sistemi 2014 Yılı Özet Raporu.

Author

SEYAHİ, Nurhan, ALTIPARMAK, Mehmet Rıza, ATEŞ, Kenan, TRABULUS, Sinan, and SÜLEYMANLAR, Gültekin

Abstract

OBJECTIVE: Turkish Society of Nephrology registry collects data on hemodialysis, peritoneal dialysis and transplantation on annual basis. Registry reports are printed every year as a booklet and this is the 24th year of registry reports. The registry is in close collaboration with international registries. MATERIAL and METHODS: In this paper data from the 2013 registry report are summarized, additionally yearly trends in the management of end stage renal disease are also provided. RESULTS: The number of patients on renal replacement therapy is rapidly increasing, at the end of 2013, 66711 patients were on renal replacement therapy. The prevalence and incidence of end stage renal disease was 870 and 138 per million population respectively. Diabetes was the most important cause of end stage renal disease. Hemodialysis (79%) was the most common type of treatment modality, followed by transplantation (14%) and peritoneal dialysis (7%). CONCLUSION: End stage renal disease is a very important and growing health problem for our country. Renal registry is a leading tool for providing current and sound data on this public health problem. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results